En route to BLA fil­ing, Ac­tini­um de­tails PhI­II win for tar­get­ed ra­dio­ther­a­py in acute myeloid leukemia

Ac­tini­um Phar­ma­ceu­ti­cals has spelled out the full Phase III da­ta for its lead tar­get­ed ra­dio­ther­a­py — one that ex­ecs say presents a “prac­tice ex­pand­ing op­por­tu­ni­ty” in acute myeloid leukemia.

In the SIER­RA tri­al, Ac­tini­um’s Iomab-B met the pri­ma­ry end­point by help­ing 22% of pa­tients achieve six-month durable com­plete re­mis­sion fol­low­ing ini­tial com­plete re­mis­sion af­ter a bone mar­row trans­plant — com­pared to 0% of the con­trol arm (p<0.0001).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER